

COMPANY OVERVIEW

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company seeking to discover and develop novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. We employ unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. These technologies are designed to efficiently deliver small molecule therapeutics that are safe, effective and convenient to administer. We have identified promising preclinical and early clinical stage antiviral therapeutics that target the replication process of influenza virus, SARS-CoV-2 virus, hepatitis C virus, and norovirus.

RECENT NEWS

Cocrystal Pharma Announces Closing of \$40 Million Bought Deal

May 7 2021, 4:05 PM EDT

Cocrystal Pharma Announces \$40 Million Bought Deal Offering of Common Stock

May 4 2021, 6:41 PM EDT

Cocrystal Pharma Provides Update on its COVID-19 Antiviral Discovery and Development Programs

May 3 2021, 8:00 AM EDT

STOCK OVERVIEW

Symbol	COCP
Exchange	Nasdaq
Market Cap	83.62m
Last Price	\$1.17
52-Week Range	\$0.76 - \$3.46

05/11/2021 04:00 PM EDT

INVESTOR RELATIONS

LHA Investor Relations
Jody Cain
T: 310-691-7100
jcain@lhai.com

MANAGEMENT TEAM

Gary Wilcox, Ph.D.

Chairman of the Board and Chief Executive Officer

Sam Lee, Ph.D.

President

James J. Martin

Chief Financial Officer

COCRYSTAL PHARMA, INC.

19805 North Creek Parkway
Bothell, WA 98011
US

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.